ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Zhou, Jianbiao ^a,b   Goh, Boon Cher ^b,c   Albert, Daniel H ^d   Chen, Chien Shing ^a,e  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d ABBOTT LABORATORIES   (United States)

^e LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CHIR 258; CISPLATIN; CYTARABINE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; N (4 (3 AMINO 1H INDAZOL 4 YL)PHENYL) N1 (2 FLUORO 5 METHYLPHENYL)UREA; N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N1-(2-FLUORO-5-METHYLPHENYL)UREA; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLISTER; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FIBROSARCOMA; GENE MUTATION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEUKEMIA; LEUKEMIA CELL LINE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MOUSE; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PROTEINURIA; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; EVALUATION; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDAZOLES; LEUKEMIA; MODELS, BIOLOGICAL; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 69249142285     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-33     Document Type: Article

References (68)

1. Oncogenic kinase signalling. P Blume-Jensen T Hunter, Nature 2001 411 355 65 10.1038/35077225 11357143 (Pubitemid 32467045)
2. Protein tyrosine phosphatases: regulatory mechanisms. J den Hertog A Ostman FD Bohmer, Febs J 2008 275 831 47 10.1111/j.1742-4658.2008.06247.x 18298791 (Pubitemid 351230200)
3. Hematopoietic receptors of class III receptor-type tyrosine kinases. O Rosnet D Birnbaum, Crit Rev Oncog 1993 4 595 613 7506935
4. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. D Small M Levenstein E Kim C Carow S Amin P Rockwell L Witte C Burrow MZ Ratajczak AM Gewirtz, Proc Natl Acad Sci USA 1994 91 459 63 7507245 10.1073/pnas.91.2.459
5. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. SD Lyman L James L Johnson K Brasel P de Vries SS Escobar H Downey RR Splett MP Beckmann HJ McKenna, Blood 1994 83 2795 801 8180375
6. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. M Nakao S Yokota T Iwai H Kaneko S Horiike K Kashima Y Sonoda T Fujimoto S Misawa, Leukemia 1996 10 1911 8 8946930
7. The roles of FLT3 in hematopoiesis and leukemia. DG Gilliland JD Griffin, Blood 2002 100 1532 42 10.1182/blood-2002-02-0492 12176867 (Pubitemid 34925124)
8. The role of FLT3 in haematopoietic malignancies. DL Stirewalt JP Radich, Nat Rev Cancer 2003 3 650 65 10.1038/nrc1169 12951584
9. FLT3: IT Does matter in leukemia. M Levis D Small, Leukemia 2003 17 1738 52 10.1038/sj.leu.2403099 12970773 (Pubitemid 37185249)
10. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. DW Sternberg JD Licht, Curr Opin Hematol 2005 12 7 13 10.1097/01.moh.0000147891.06584.d7 15604885 (Pubitemid 40189233)
11. The biology of VEGF and its receptors. N Ferrara HP Gerber J LeCouter, Nat Med 2003 9 669 76 10.1038/nm0603-669 12778165 (Pubitemid 36749215)
12. Tumorigenesis and the angiogenic switch. G Bergers LE Benjamin, Nat Rev Cancer 2003 3 401 10 10.1038/nrc1093 12778130 (Pubitemid 37328844)
13. The role of the tumor microenvironment in hematological malignancies and implication for therapy. J Zhou K Mauerer L Farina JG Gribben, Front Biosci 2005 10 1581 96 10.2741/1642 15769648
14. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. S Dias K Hattori Z Zhu B Heissig M Choy W Lane Y Wu A Chadburn E Hyjek M Gill DJ Hicklin L Witte MA Moore S Rafii, J Clin Invest 2000 106 511 21 10953026 10.1172/JCI8978
15. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. W Fiedler U Graeven S Ergun S Verago N Kilic M Stockschlader DK Hossfeld, Blood 1997 89 1870 5 9058706
16. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. AF List B Glinsmann-Gibson C Stadheim EJ Meuillet W Bellamy G Powis, Exp Hematol 2004 32 526 35 10.1016/j.exphem.2004.03.005 15183893 (Pubitemid 38739464)
17. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. SC Santos S Dias, Blood 2004 103 3883 9 10.1182/blood-2003-05-1634 14726393 (Pubitemid 38596309)
18. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. DH Albert P Tapang TJ Magoc LJ Pease DR Reuter RQ Wei J Li J Guo PF Bousquet NS Ghoreishi-Haack B Wang GT Bukofzer YC Wang JA Stavropoulos K Hartandi AL Niquette N Soni EF Johnson JO McCall JJ Bouska Y Luo CK Donawho Y Dai PA Marcotte KB Glaser MR Michaelides SK Davidsen, Mol Cancer Ther 2006 5 995 1006 10.1158/1535-7163.MCT-05-0410 16648571 (Pubitemid 43724600)
19. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5- methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. Y Dai K Hartandi Z Ji AA Ahmed DH Albert JL Bauch JJ Bouska PF Bousquet GA Cunha KB Glaser CM Harris D Hickman J Guo J Li PA Marcotte KC Marsh MD Moskey RL Martin AM Olson DJ Osterling LJ Pease NB Soni KD Stewart VS Stoll P Tapang DR Reuter SK Davidsen MR Michaelides, J Med Chem 2007 50 1584 97 10.1021/jm061280h 17343372 (Pubitemid 46564379)
20. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. J Guo PA Marcotte JO McCall Y Dai LJ Pease MR Michaelides SK Davidsen KB Glaser, Mol Cancer Ther 2006 5 1007 13 10.1158/1535-7163.MCT-05-0359 16648572 (Pubitemid 43724601)
21. Cellular activity of ABT-869 against colony-stimulating-factor-1 receptor (CSF-1R) in macrophage-like cell lines [abstract]. TWJP Li, Proceedings of the 100th Annual Meeting of the American Association for Cancer Research Denver, CO: Philadelphia (PA): AACR 2009 Abstract nr 1789
22. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. J Zhou M Pan Z Xie SL Loh C Bi YC Tai M Lilly YP Lim JH Han KB Glaser DH Albert SK Davidsen CS Chen, Leukemia 2008 22 138 46 10.1038/sj.leu.2404960 17943175
23. The RTK inhibitor ABT-869, alone and in combination with paclitaxel and/or zoledronic acid, demonstrates significant reduction in the development of both osteoblastic (LuCap 23.1) and osteolytic (PC3-M-Luciferase) tumors intratibially. HJ Donawho C YC Wang G Bukofzer Y Dai S Davidsen B Wang S Schlessinger D Frost, AACR Meeting Abstracts 2007 2007 C204
24. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. VJ Jasinghe Z Xie J Zhou J Khng LF Poon P Senthilnathan KB Glaser DH Albert SK Davidsen CS Chen, J Hepatol 2008 49 985 97 10.1016/j.jhep.2008.08.010 18930332
25. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. L Li X Lin AR Shoemaker DH Albert SW Fesik Y Shen, Clin Cancer Res 2006 12 4747 54 10.1158/1078-0432.CCR- 05-2842 16899626 (Pubitemid 44297829)
26. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. KT Kim K Baird JY Ahn P Meltzer M Lilly M Levis D Small, Blood 2005 105 1759 67 10.1182/blood-2004-05-2006 15498859 (Pubitemid 40223700)
27. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. DB Shankar J Li P Tapang J Owen McCall LJ Pease Y Dai RQ Wei DH Albert JJ Bouska DJ Osterling J Guo PA Marcotte EF Johnson N Soni K Hartandi MR Michaelides SK Davidsen SJ Priceman JC Chang K Rhodes N Shah TB Moore KM Sakamoto KB Glaser, Blood 2007 109 3400 8 17209055 10.1182/blood-2006-06-029579 (Pubitemid 46572529)
28. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. P Brown M Levis E McIntyre M Griesemer D Small, Leukemia 2006 20 1368 76 10.1038/sj.leu.2404277 16761017 (Pubitemid 44084049)
29. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. W Fiedler R Mesters H Tinnefeld S Loges P Staib U Duhrsen M Flasshove OG Ottmann W Jung F Cavalli R Kuse J Thomalla H Serve AM O'Farrell M Jacobs NM Brega P Scigalla DK Hossfeld WE Berdel, Blood 2003 102 2763 7 10.1182/blood-2002-10-2998 12843001 (Pubitemid 37248845)
30. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. AM O'Farrell TJ Abrams HA Yuen TJ Ngai SG Louie KW Yee LM Wong W Hong LB Lee A Town BD Smolich WC Manning LJ Murray MC Heinrich JM Cherrington, Blood 2003 101 3597 605 10.1182/blood-2002-07-2307 12531805 (Pubitemid 36857948)
31. Phase 1 study of PTK787/ZK 22 a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. GJ Roboz FJ Giles AF List JE Cortes R Carlin M Kowalski S Bilic E Masson M Rosamilia MW Schuster D Laurent EJ Feldman, Leukemia 2584 20 952 7 10.1038/sj.leu.2404213
32. In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. J Zhou J Khng VJ Jasinghe C Bi CH Neo M Pan LF Poon Z Xie H Yu AE Yeoh Y Lu KB Glaser DH Albert SK Davidsen CS Chen, Leuk Res 2008 32 1091 100 10.1016/j.leukres.2007.11.025 18160102
33. Angiogenesis in ischemic and neoplastic disorders. GL Semenza, Annu Rev Med 2003 54 17 28 10.1146/annurev.med.54.101601.152418 12359828 (Pubitemid 37386383)
34. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. R Yamaguchi H Yano A Iemura S Ogasawara M Haramaki M Kojiro, Hepatology 1998 28 68 77 10.1002/hep.510280111 9657098 (Pubitemid 28299987)
35. mTOR pathway and mTOR inhibitors as agents for cancer therapy. P Baldo S Cecco E Giacomin R Lazzarini B Ros S Marastoni, Curr Cancer Drug Targets 2008 8 647 65 10.2174/156800908786733513 19075588
36. TOR, a central controller of cell growth. T Schmelzle MN Hall, Cell 2000 103 253 62 10.1016/S0092-8674(00)00117-3 11057898
37. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. TA Yap MD Garrett MI Walton F Raynaud JS de Bono P Workman, Curr Opin Pharmacol 2008 8 393 412 10.1016/j.coph.2008.08.004 18721898
38. Molecular targeted therapies in hepatocellular carcinoma. JM Llovet J Bruix, Hepatology 2008 48 1312 27 10.1002/hep.22506 18821591
39. Molecularly targeted therapy for hepatocellular carcinoma. S Tanaka S Arii, Cancer Sci 2009 100 1 8 10.1111/j.1349-7006.2008.01006.x 19038007
40. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. M Guba P von Breitenbuch M Steinbauer G Koehl S Flegel M Hornung CJ Bruns C Zuelke S Farkas M Anthuber KW Jauch EK Geissler, Nat Med 2002 8 128 35 10.1038/nm0202-128 11821896 (Pubitemid 34155123)
41. mTOR and P70 S6 kinase expression in primary liver neoplasms. F Sahin R Kannangai O Adegbola J Wang G Su M Torbenson, Clin Cancer Res 2004 10 8421 5 10.1158/1078-0432.CCR-04-0941 15623621 (Pubitemid 40053405)
42. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. DJ DeAngelo RM Stone ML Heaney SD Nimer RL Paquette RB Klisovic MA Caligiuri MR Cooper JM Lecerf MD Karol S Sheng N Holford PT Curtin BJ Druker MC Heinrich, Blood 2006 108 3674 81 16902153 10.1182/blood-2006-02-005702 (Pubitemid 44864544)
43. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. W Fiedler H Serve H Dohner M Schwittay OG Ottmann AM O'Farrell CL Bello R Allred WC Manning JM Cherrington SG Louie W Hong NM Brega G Massimini P Scigalla WE Berdel DK Hossfeld, Blood 2005 105 986 93 10.1182/blood-2004-05-1846 15459012 (Pubitemid 40170865)
44. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. S Knapper AK Burnett T Littlewood WJ Kell S Agrawal R Chopra R Clark MJ Levis D Small, Blood 2006 108 3262 70 10.1182/blood-2006-04- 015560 16857985 (Pubitemid 44776862)
45. FLT3 mutations: biology and treatment. D Small, Hematology Am Soc Hematol Educ Program 2006 178 84 17124058
46. Chronic myelogenous leukemia. BJ Druker CL Sawyers R Capdeville JM Ford M Baccarani JM Goldman, Hematology (Am Soc Hematol Educ Program) 2001 87 112 11722980
47. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. ME Gorre M Mohammed K Ellwood N Hsu R Paquette PN Rao CL Sawyers, Science 2001 293 876 80 10.1126/science.1062538 11423618 (Pubitemid 32743979)
48. Bis(1H-indol-2-yl)methanones are effective inhibitors of mutated FLT3 tyrosine kinase, overcome resistance to PKC421A in vitro and show synergy with chemotherapy. MF Heidel F F Breitenbucher S Dove C Huber FD Bohmer T Ficher, Blood 2006 108
49. Frolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. O Piloto M Wright P Brown KT Kim M Levis D Small, Blood 2007 109 1643 52 17047150 10.1182/blood-2006-05-023804 (Pubitemid 46239599)
50. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. J Zhou C Bi JV Janakakumara SC Liu WJ Chng KG Tay LF Poon Z Xie S Palaniyandi H Yu KB Glaser DH Albert SK Davidsen CS Chen, Blood 2009 113 4052 62 10.1182/blood-2008-05-156422 19144991
51. The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways. S Wormald DJ Hilton, Curr Opin Hematol 2007 14 9 15 10.1097/00062752-200701000-00004 17133094
52. Stat proteins and oncogenesis. J Bromberg, J Clin Invest 2002 109 1139 42 11994401
53. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. C Hannum J Culpepper D Campbell T McClanahan S Zurawski JF Bazan R Kastelein S Hudak J Wagner J Mattson, Nature 1994 368 643 8 10.1038/368643a0 8145851 (Pubitemid 24153389)
54. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. LS Rusten SD Lyman OP Veiby SE Jacobsen, Blood 1996 87 1317 25 8608220
55. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. U Dehmel M Zaborski G Meierhoff O Rosnet D Birnbaum WD Ludwig H Quentmeier HG Drexler, Leukemia 1996 10 261 70 8637235
56. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. R Zheng M Levis O Piloto P Brown BR Baldwin NC Gorin M Beran Z Zhu D Ludwig D Hicklin L Witte Y Li D Small, Blood 2004 103 267 74 10.1182/blood-2003-06-1969 12969963 (Pubitemid 38029948)
57. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. B Scheijen HT Ngo H Kang JD Griffin, Oncogene 2004 23 3338 49 10.1038/sj.onc.1207456 14981546 (Pubitemid 38669823)
58. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. G Ambrosini C Adida DC Altieri, Nat Med 1997 3 917 21 10.1038/nm0897-917 9256286 (Pubitemid 27353455)
59. Survivin as a target for new anticancer interventions. N Zaffaroni M Pennati MG Daidone, J Cell Mol Med 2005 9 360 72 10.1111/j.1582-4934.2005. tb00361.x 15963255
60. Survivin, a cancer target with an emerging role in normal adult tissues. S Fukuda LM Pelus, Mol Cancer Ther 2006 5 1087 98 10.1158/1535-7163.MCT-05-0375 16731740 (Pubitemid 43881300)
61. Survivin, cancer networks and pathway-directed drug discovery. DC Altieri, Nat Rev Cancer 2008 8 61 70 10.1038/nrc2293 18075512
62. Validating survivin as a cancer therapeutic target. DC Altieri, Nat Rev Cancer 2003 3 46 54 10.1038/nrc968 12509766 (Pubitemid 37328886)
63. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. S Nam R Buettner J Turkson D Kim JQ Cheng S Muehlbeyer F Hippe S Vatter KH Merz G Eisenbrand R Jove, Proc Natl Acad Sci USA 2005 102 5998 6003 15837920 10.1073/pnas.0409467102 (Pubitemid 40594244)
64. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. CI Wong TS Koo R Soo S Hartono CH Thng E McKeegan WP Yong CS Chen SC Lee J Wong R Lim N Sukri SE Lim AB Ong J Steinberg N Gupta R Pradhan R Humerickhouse BC Goh, Journal of Clinical Oncology 2009
65. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. H Toh P Chen BI Carr JJ Knox S Gill J Steinberg DM Carlson J Qian Q Qin W Yong, J Clin Oncol 2009 27 20 e15 e17 http://meeting.ascopubs.org/cgi/ content/abstract/27/15S/4581 10.1200/JCO.2008.21.7695 19433680
66. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. N Tannir Y Wong C Kollmannsberger MS Ernstoff DJ Perry LJ Appleman E Posadas J Qian JL Ricker DM Michaelson, J Clin Oncol 2009 27 15s http://meeting.ascopubs.org/cgi/content/ abstract/27/15S/5036 10.1200/JCO.2008.21.7695
67. ABT-869 in non-small cell lung cancer (NSCLC): Interim results. E Tan R Salgia B Besse G Goss DR Gandara N Hanna J Steinberg J Steinberg J Qian DM Carlson R Soo, Clin Oncol 2009 27 15s http://meeting.ascopubs.org/cgi/content/ abstract/27/15S/8074 10.1200/JCO.2008.21.7695
68. Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients. N Gupta PM Diderichsen J Steinberg JL Ricker R Humerickhouse W Awni R Pradhan, J Clin Oncol 2009 27 15s http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3567 10.1200/JCO.2008.21.7695